We silence genes to fight disease
At Dicerna, we create medicines that selectively silence the genes that cause or contribute to disease using RNA interference, or RNAi. We are leaders in RNAi, harnessing the potential of this powerful and complex process to create medicines that aim to enhance the health and extend the lives of patients with rare and common diseases.
We go right to the source
Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop RNAi therapies that aim to target and silence genes that cause or contribute to disease. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.
Our team aims to deliver
Dicerna brings together talented experts in biology, chemistry, clinical science, medicine and commercial development. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge, experience and sense of urgency needed to realize the full potential of RNAi technology and expedite the development of new therapies.
Our purpose is clear: delivering life-changing therapies as efficiently and quickly as possible to help people living with rare and common diseases.
Dicerna overview
Offices:
Lexington, Mass.
Boulder, Colo.
2007
Founded
300+
Employees
Grants & Charitable Donations
Industry Support
As part of our commitment to patients, Dicerna supports programs and activities that foster excellence in patient care and provide valuable scientific, medical and educational information to the medical and scientific communities as well as patient advocacy organizations. Learn more here about Dicerna’s Industry Support program.
